# Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

> **NCT02646748** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 159 (actual)

## Conditions studied

- Colorectal Cancer (CRC)
- Endometrial Cancer
- Melanoma
- Head and Neck Cancer
- Lung Cancer
- MMR-deficient Tumors
- Breast Cancer
- Pancreatic Cancer
- Renal Cell Carcinoma (RCC)
- Solid Tumors
- UC (Urothelial Cancer)

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** itacitinib
- **DRUG:** INCB050465

## Key facts

- **NCT ID:** NCT02646748
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-25
- **Primary completion:** 2019-11-07
- **Final completion:** 2020-11-20
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02646748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02646748, "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02646748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*